SCHEMBL8317054

SCHEMBL8317054

O=C(O)C1OC(O)CS1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8806821 1.00
SCHEMBL8317048 1.00
SCHEMBL8806439 1.00
SCHEMBL17683594 0.76
SCHEMBL7868218 0.74
SCHEMBL8874188 0.74
SCHEMBL13051904 0.74
SCHEMBL12996745 0.74 PPM1B (0.35)
SCHEMBL27869449 0.71
SCHEMBL6313676 0.70 PPM1B (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110467608-B Synthetic method of emtricitabine 武汉工程大学 2023-04-07 CN claimed
CN-102911167-A Method for preparing nucleoside intermediate with high optical purity UNIV HEFEI TECHNOLOGY 2013-02-06 CN claimed
CN-102234269-A Industrial preparation method for lamivudine CHONGQING PHARM RES INST CO 2011-11-09 CN claimed
CN-1274686-C Suitable industrialized method of preparing Lamivudine JIUCHUANG CHEMICAL CO LTD JINA (CN) 2006-09-13 CN claimed
CN-1563003-A Suitable industrialized method of preparing Lamivudine JIUCHUANG CHEMICAL CO LTD JINA (CN) 2005-01-12 CN claimed
CN-1563002-A Suitqable to industrialized method for preparing emtricitabine JIUCHUANG CHEMICAL CO LTD JINA (CN) 2005-01-12 CN claimed
US-5693787-A Intermediates in the synthesis of 1,3-oxathiolanyl cytosine nucleoside analogues BIOCHEM PHARMA INC. (CA) 1997-12-02 US claimed
EP-0515157-B1 Processes for the diastereoselective synthesis of nucleosides IAF BIOCHEM INT (CA) 1997-09-03 EP claimed
WO-1992020669-A1 PROCESSES FOR THE DIASTEREOSELECTIVE SYNTHESIS OF NUCLEOSIDES BIOCHEM PHARMA INC. (CA) 1992-11-26 WO claimed
EP-0515157-A1 Processes for the diastereoselective synthesis of nucleosides BIOCHEM PHARMA INC. (CA) 1992-11-25 EP claimed
EP-3695837-B1 A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR FOR TREATING HEPATITIS B HOFFMANN LA ROCHE (CH) 2024-11-20 EP disclosed
US-11771699-B2 Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor HOFFMANN-LA ROCHE INC. (US) 2023-10-03 US disclosed
US-11771699-B2 Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor HOFFMANN-LA ROCHE INC. (US) 2023-10-03 US disclosed
US-11771699-B2 Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor HOFFMANN-LA ROCHE INC. (US) 2023-10-03 US disclosed
CN-116199679-A Industrial preparation method of lamivudine 吉斯凯(苏州)制药有限公司 2023-06-02 CN disclosed
US-5693787-A Intermediates in the synthesis of 1,3-oxathiolanyl cytosine nucleoside analogues BIOCHEM PHARMA INC. (CA) 1997-12-02 US disclosed
EP-0515157-B1 Processes for the diastereoselective synthesis of nucleosides IAF BIOCHEM INT (CA) 1997-09-03 EP disclosed
US-5663320-A Processes for the diastereoselective separation of nucleoside analogue synthetic intermediates BIOCHEM PHARMA, INC. (CA) 1997-09-02 US disclosed
WO-1992020669-A1 PROCESSES FOR THE DIASTEREOSELECTIVE SYNTHESIS OF NUCLEOSIDES BIOCHEM PHARMA INC. (CA) 1992-11-26 WO disclosed
EP-0515157-A1 Processes for the diastereoselective synthesis of nucleosides BIOCHEM PHARMA INC. (CA) 1992-11-25 EP disclosed